References
- Bayer HealthCare Pharmaceuticals Inc. (2019). Nubeqa (darolutamide) US prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212099Orig1s000lbl.pdf [last accessed 13 Dec 2019].
- Borgmann H, Lallous N, Ozistanbullu D, et al. (2018). Moving towards precision urologic oncology: targeting enzalutamide-resistant prostate cancer and mutated forms of the androgen receptor using the novel inhibitor darolutamide (ODM-201). Eur Urol 73:4–8.
- Caldwell J, Gardner I, Swales N. (1995). An introduction to drug disposition: the basic principles of absorption, distribution, metabolism, and excretion. Toxicol Pathol 23:102–14.
- European Medicines Agency. (2011). Guideline on bioanalytical method validation. Available from: https://www.ema.europa.eu/documents/scientific-guideline/guideline-bioanalytical-method-validation_en.pdf [last accessed 21 Feb 2019].
- Fizazi K, Massard C, Bono P, et al. (2014). Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 15:975–85.
- Fizazi K, Shore N, Tammela TL, et al. (2019). Darolutamide in nonmetastatic, castration-resistant prostate cancer. N Engl J Med 380:1235–46.
- Food and Drug Administration. (2018). Bioanalytical method validation: guidance for industry. Available from: https://www.fda.gov/downloads/Drugs/Guidances/ucm070107.pdf [last accessed 21 Feb 2019]
- Graham L, Schweizer M. (2016). Targeting persistent androgen receptor signaling in castration-resistant prostate cancer. Med Oncol 33:44.
- Graham MJ, Lake BG. (2008). Induction of drug metabolism: species differences and toxicological relevance. Toxicology 254:184–91.
- Massard C, Fizazi K. (2011). Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res 17:3876–83.
- Massard C, Penttinen HM, Vjaters E, et al. (2016). Pharmacokinetics, antitumor activity, and safety of ODM-201 in patients with chemotherapy-naive metastatic castration-resistant prostate cancer: an open-label phase 1 study. Eur Urol 69:834–40.
- Moilanen AM, Riikonen R, Oksala R, et al. (2015). Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 5:12007.
- Mottet N, Bellmunt J, Bolla M, et al. (2017). EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 71:618–29.
- National Comprehensive Cancer Network. (2019). National Comprehensive Cancer Network clinical practice guidelines in oncology: Prostate cancer (v4.2019). Available from: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. [last accessed 7 Nov 2019.
- Parker C, Gillessen S, Heidenreich A, Horwich A. (2015). Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 26:v69–77.
- Ritschel WA, Kearns GL. (2009). Handbook of basic pharmacokinetics, including clinical applications. 7th Edition. Washington, DC: American Pharmaceutical Association.
- Sugawara T, Baumgart SJ, Nevedomskaya E, et al. (2019). Darolutamide is a potent androgen receptor antagonist with strong efficacy in prostate cancer models. Int J Cancer 145:1382–94.
- Zurth C, Koskinen M, Fricke R, et al. (2019). Drug–drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet 44:747–59.